



final

**GYNECOLOGIC CANCER INTERGROUP (GCI)  
ENDOMETRIAL CANCER COMMITTEE MEETING  
TUESDAY, NOV.10, 2015 , 4:00PM – 6:00PM  
3F ROOM, JIKEI UNIVERSITY, TOKYO**

***PLEASE SIGN ATTENDANCE FORMS***

**CHAIR: K.LORUSSO CO-CHAIR: S.GREGGI PAST CHAIR: D.MILLER**

**HARMONIZATION LIAISONS: K.ADEMA/T.KIRKEGAARD (OPS); D.TU/A.EMBLETON (STATS)**

**AGENDA**

**Present:**

**Regrets:**

**Welcome and Introductions and COI Disclosures (real or perceived) Lorusso  
Approval of minutes: May 2015**

**GCIG STUDIES FOR BRIEF UPDATES & REVIEW: 30 MINUTES Lorusso**

**CLOSED TRIALS:**

**Endometrial Staging**

- **KGOG 2015:** Multi-center Prospective Observational Study for the Validation of Preoperative Low-risk Criteria for Lymph Node Metastasis in Endometrial Cancer (NCT01527396) (*?? other GCIG groups ??*)

**Endometrial Adjuvant**

- **DGOG PORTEC-3:** Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma (NCT00411138) – **MaNGO, ANZGOG, NCRI, and NCIC-CTG. NSGO interested.**

- **GOG-0258:** A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial (NCT00942357) – **RTOG**

**Endometrial Advanced/Recurrent:**

- **GOG-0238:** A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus (NCT00492778) – **RTOG .**

**Endometrial Rare:**

- **Uterine Carcinosarcoma GOG-0261:** A Randomized Phase III trial of Carboplatin plus Paclitaxel VERSUS Ifosfamide plus Paclitaxel in Chemotherapy Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus (NCT00954174) – **Interested: NCRI, GINECO, JGOG, RTOG Miller**

**ONGOING TRIALS:**

**Endometrial Conservative Treatment**

- Conservative treatment of endometrial cancer; a multicentre registry study K. Lorusso for S. Greggi

**Endometrial Adjuvant**

- **DGCG**: A Phase III Trial of Postoperative Chemotherapy or no Further Treatment for Patients With Node-negative Stage I-II Intermediate or High Risk Endometrial Cancer (NCT01244789): **NSGO, AGO, BGOG, EORTC, MANGO, MITO**

- **DGOG PORTEC4**: Randomized trial of vaginal brachytherapy vs observation for high-intermediate risk endometrial carcinoma

**Endometrial Follow Up**

- **MaNGO TOTEM Trial**: Appropriateness Evaluation of Follow up Procedures in Gynaecology Oncology **TOTEM** Study: Multicentric Randomized Controlled Clinical Trial Between Two Follow up Regimens With Different Tests Intensity in Endometrial Cancer Treated Patients (NCT00916708)

**Endometrial Rare:**

- **Endometrial Clear Cell NiCCC**: Randomised Phase II Study of BIBF 1120 compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium" **SGCTG, NSGO, EORTC, GINECO**

- **Uterine Leiomyosarcoma GOG0277 (UC1009)**: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) v. Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma (NCT01533207).

**ACIVATING TRIALS:**

**Endometrial Surgery:**

-Lymphadenectomy STATEC trial

**Kitchner 10 MINUTES**

**Endometrial Advanced/Recurrent:**

-**NSGO**: A randomized phase II trial of first line combination chemotherapy with BIBF1120/placebo for patients with advanced or recurrent endometrial cancer.

**Mirza 10 MINUTES**

**Conservative treatment**

**Endometrial Adjuvant:**

-A randomized phase III study of standard vs. IMRT pelvic radiation for post-operative treatment of endometrial and cervical cancer (time-c)

**David Gaffney 10 minutes**

**NEW PROPOSALS:**

-Assessing the uterus following pelvic radiation: observational Registry

**M. Quinn**

**Trophoblastic neoplasia:**

- **GOG0275 (UC1005)**: A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia (NCT01535053):

- **GOG/ISSTD**: A randomized phase II trial comparing the toxicity of paclitaxel etoposide (TE) alternating two weekly with paclitaxel and cisplatin (TP) with etoposide and cisplatin (EP) alternating weekly with etoposide, methotrexate and dactinomycin (EMA) in GTN patients failing non platinum based combination agent therapies. **Seckl**

**Challenging debate:**

**ENDOMETRIAL CANCER : GENETIC PROFILE AND IMPLICATION FOR  
ANTIANGIOGENIC AGENTS AND IMMUNOTHERAPY**

**E. Kohn 20 minutes**

**Discussion and take home message**

**ADJOURN**